Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/02/2016 12/05/2016 12/06/2016 12/07/2016 12/08/2016 Date
15.45(c) 15.75(c) 15.8(c) 14.925(c) 15.2(c) Last
587 072 532 330 413 130 1 110 001 1 038 807 Volume
-2.22% +1.94% +0.32% -5.54% +1.84% Change
More quotes
Financials ($)
Sales 2016 223 M
EBIT 2016 107 M
Net income 2016 25,2 M
Debt 2016 141 M
Yield 2016 -
Sales 2017 227 M
EBIT 2017 131 M
Net income 2017 63,9 M
Debt 2017 93,6 M
Yield 2017 -
P/E ratio 2016 27,99
P/E ratio 2017 10,18
EV / Sales2016 3,70x
EV / Sales2017 3,42x
Capitalization 684 M
More Financials
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs in the Americas, Europe and Asia.It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic and... 
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUCAMPO PHARMACEUTICALS, I
11/16 BUYINS.NET : CENX, AIXG, GBDC, MSCI, SCMP, RPG Are Seasonally Ripe To Go Up In t..
11/09 SUCAMPO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
11/09 U.S. companies react cautiously to Trump victory
11/09 SUCAMPO PHARMACEUTICALS : tops Street 3Q forecasts
11/09 SUCAMPO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, R..
11/09 Sucampo Reports Third Quarter 2016 Financial Results
10/28 Sucampo Announces Third Quarter 2016 Earnings Call
08/26 SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form ..
08/08 SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form ..
08/03 SUCAMPO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on SUCAMPO PHARMACEUTICALS, I 
2015The bullish trend is not over
More Strategies
News from SeekingAlpha
11/28 A Company On The Verge Of Profiting
11/13 Pick Up Shares Of These 4 Earnings Winners
11/09 Sucampo Pharmaceuticals, Inc. 2016 Q3 - Results - Earnings Call Slides
11/09 Sucampo Pharmaceuticals' (SCMP) CEO Peter Greenleaf on Q3 2016 Results - Earn..
11/09 Midday Gainers / Losers
Advertisement
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Full-screen chart
Technical analysis trends SUCAMPO PHARMACEU...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 20,1 $
Spread / Average Target 35%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Peter S. Greenleaf Chairman & Chief Executive Officer
Andrew P. Smith Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Daniel P. Getman Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICAL..-13.68%684
AMGEN, INC.-13.02%105 034
GILEAD SCIENCES, INC.-28.08%95 884
CELGENE CORPORATION-5.93%87 334
REGENERON PHARMACEUTIC..-33.32%38 181
ACTELION LTD45.20%22 191
More Results